Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Monensin shows promise as a molecular scaffold for inhibiting AML
Key clinical point: Monensin and related compounds are promising molecular scaffolds for development of novel MYB inhibitors.
Major finding: Monensin significantly inhibits proliferation of primary AML cells but not of normal hematopoietic progenitors.
Study details: Metabolic analysis and treatment of acute myeloid leukemia cell lines.
Disclosures: The study was sponsored by the Swedish state. The authors reported they had no conflicts of interest.
Citation:
Yusenko MV et al. Cancer Letters. 2020;479:61-70. https://doi.org/10.1016/j.canlet.2020.01.039